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ABSTRACT:  The relative roles of SULF1 and SULF2 enzymes in tumour growth are 
controversial but short SULF1/SULF2 splice variants predominate in human 
mammary tumours despite their non-detectable levels in normal mammary tissue. 
Compared with the normal, the level of receptor tyrosine kinase (RTK) activity was 
markedly increased in triple positive mammary tumours during later stages of tumour 
progression showing increased p-EGFR, p-FGFR1 and p-cMet activity in triple 
positive but not in triple negative tumours.  The abundance of catalytically inactive 
short SULF1/SULF2 variants permits high levels of HS sulfation and thus growth 
driving RTK cell signalling in primary mammary tumours. Also observed in this study, 
however, was increased N-sulfation detected by antibody 10E4 indicating that not 
only 6-O sulfation but also N-sulfation may contribute to increased RTK cell 
signalling in mammary tumours.  The levels of such increases in not only 
SULF1/SULF2 but also in pEGFR, pFGFR1, p-cMet and Smad1/5/8 signalling were 
further enhanced following lymph node metastasis. The over-expression of Sulf1and 
Sulf2 variants in mammary tumour-derived MDA-MB231 and MCF7 cell lines by 
transfection further confirms Sulf1/Sulf2-mediated differential modulation of growth. 
The short variants of both Sulf1 and Sulf2 promoted FGF2-induced MDA-MB231 and 
MCF7 in vitro growth while full length Sulf1 inhibited growth supporting in vivo 
mammary tumour cell signalling patterns of growth.  Since a number of mammary 
tumours become drug resistant to hormonal therapy, Sulf1/Sulf2 inhibition could be 
an alternative therapeutic approach to target such tumours by downregulating RTK-
mediated cell signalling. 
 
Introduction: Mammary tumours represent the most common cancer amongst 
women but like many other cancers it is molecularly heterogeneous and highly 
variable in its therapeutic response and metastatic properties (Engstrøm MJ et al. 
2013). Molecular subtyping of this cancer provides some prognostic information 
regarding the most likely clinical outcomes.  The most widely used markers for tissue 
biopsy characterisation include the positive or negative expression of estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER-2), often described as triple positive or triple negative cancers. 
Many triple positive tumours are successfully treated over a number of years 
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although a proportion of them become drug resistant over time and thus effectively 
untreatable as are a large majority of the drug non-responsive triple negative 
cancers (Clarke R et al. 2015). It would thus help to discern the key drivers of breast 
tumour growth to enable targeting alternative signalling pathways to overcome drug 
resistant cell survival.  
 
Cell signalling is one of the key drivers of tumour growth but most cancers activate 
not one but multiple signalling pathways. Targeting one specific cell signalling 
pathway often activates alternative pathways.  While it is desirable to devise specific 
targets, the inhibition of multiple pathways may in some cases be more effective. For 
example, targeting co-receptors such as heparan sulfate proteoglycans (HSPGs) or 
their modifying enzymes may inhibit multiple cancer signalling pathways considering 
that the expression of HSPGs and their associated enzymes markedly change 
during tumour growth. Heparan sulfate (HS) chains of glycosaminoglycans (GAGs) 
in HSPGs are made up of repeating disaccharide units of glucuronic/iduronic acid 
and glucosamine that show further modifications of their properties generated by 
deacetylation, epimerization and sulfation at the N-, 3-O, and 6-O positions of 
glucosamine and the 2-O position of the iduronic acid residue.  Changes in their HS 
sulfation patterns can exert differential functional effects on cell signalling and thus 
drive not only regulated normal development but also dysregulated tumour growth. 
Of particular interest amongst these changes is the 6-O sulfate group of the HS 
chains that has been shown to be associated with the regulation of a number of 
growth factor signalling pathways (Lamanna et al. 2007). The significance of 6-O 
sulfation in cell signalling has been further highlighted by the discovery of 
extracellular editing of HS sulfation by two cell surface sulfatases, Sulf1 (qSulf1) and 
Sulf2, which specifically hydrolyse glucosamine-6S groups of the HS chain (Dhoot et 
al. 2001; Morimoto-Tomita et al. 2002). Reduction in 6-O HS sulfation promotes 
certain cell signalling pathways such as Wnt and GDNF but inhibits others, for 
example tyrosine kinase receptor mediated FGF-2, HB-EGF and HGF pathways. 
Sulf1/Sulf2 regulation of 6-O HS sulfation thus has the potential to control cell growth 
and migration by regulating the activities of specific cell signaling pathways. 
 
Both Sulf1 and Sulf2 have been shown to be upregulated in a number of cancer 
types (Bret et al. 2011; Gill et al. 2012; Gill et al. 2014; Nawroth et al. 2007; 
Lemjabbar-Alaoui et al. ; Phillips JJ et al. 2012) although some others have reported 
the down-regulation of Sulf1 in mammary tumours (Lai et al. 2006; Narita et al. 2007; 
Lai et al. 2008) since they describe Sulf1 as a tumour suppressor but Sulf2 as a 
tumour enhancer.  Some such differences may relate to in vivo primary tumours 
versus in vitro cell line comparisons. While a number of tumour studies report the 
investigation of primary tumours many also invest a lot of effort in tumour derived cell 
lines, with each cell line representing a single patient considering that no two 
tumours are identical and even a single tumour demonstrates extensive spatial and 
temporal evolvement over time (Gill et al. 2014). The limited in vitro cell line analyses 
thus may not replicate the in vivo tumour growth patterns. The in vitro growth of cell 
lines also lacks in vivo competition for survival due to unsustainable active in vivo 
growth and stromal infiltration. The cell lines themselves can also evolve during 
different culture conditions and one has to bear in mind that normal mammary tissue 
does not express detectable levels of either Sulf1or Sulf2 proteins although low level 
of mRNA can be detected using multiple RT PCR amplification cycles (Morimoto-
3 
 
Tomita et al. 2005). Cell lines nevertheless are a useful tool to investigate the role of 
different components in cell signalling and growth.   
 
The additional problem of Sulf1/Sulf2 analysis of any pathological tissue and 
particularly the tumour tissues relates to the generation of multiple splice variants 
with different functional activities (Sahota and Dhoot 2009; Gill et al. 2011; Gill et al. 
2012; Gill et al. 2014) that so far has received little attention. Lack of attention to 
splice variant diversity is even more misleading for those tumours in which the short 
variants of both Sulf1 and Sulf2 predominate during most stages of growth. The lack 
of catalytic activity in such shorter variants can completely change their cell 
signalling function.  The present study therefore was undertaken to determine the 
nature of Sulf1 and Sulf2 variants in mammary tumours and to determine whether 
their ectopic expression alters tumour growth. This study demonstrates the 
abundance of shorter variants of both Sulf1 and Sulf2 in mammary tumours although 
low levels of full length isoforms were also detectable in such tissues. These tumours 
also demonstrate the up-regulation of RTK-mediated cell signalling pathways whose 
activities would be protected by shorter Sulf variants unlike the inhibitory effects of 
full length Sulf1 on RTK-mediated pathways. The in vitro ectopic expression of full 
length and Short Sulf1 and Sulf2 splice variants further  supports their differential 
functions in mammary tumour-derived cell lines and their patterns of growth although 
most primary tumours as well as cell lines often express more than one variant in the 




Expression patterns of SULF1/SULF2 variants in mammary tumours: Neither 
SULF1 and nor SULF2 is detectable in normal mammary tissues using the 
immunohistochemical staining procedure (Figures 1 & 2). Low level SULF1 and or 
SULF2 expression is, however, detectable in some benign and hyperplastic samples 
(Figures 1 & 2). The onset of SULF1 expression and its persistence during all stages 
becomes increasingly clear in both triple positive and triple negative malignant 
tissues (Figures 1 & 2). SULF2 expression is also observed in all mammary tumours 
although the level of this enzyme was lower in triple positive compared with triple 
negative tumours (Figure 2). The shorter variants of both SULF1 and SULF2 
enzymes were the most abundant isoforms in all mammary tumours. The levels of 
full length SULF2 and particularly SULF1 were low in all such tumours.  While 
SULF1 expression appeared to be mainly in the epithelial or mesenchymal cells 
during all stages, the expression of SULF2 appeared relatively more abundant in the 
stromal tissue in both triple positive and triple negative tumours (Figure 2). The level 
of SULF1 in triple positive tissues was considerably higher than levels of SULF2 in 
such tumours while both SULF1 and SULF2 predominated in triple negative 
samples. The levels of full length SULF2 and particularly full length SULF1 in such 
tumours in comparison was much lower. 
 
Cell signalling in mammary tumours: To determine if the low level expression of 
full length SULF1/SULF2 compared with much higher expression of their shorter 
variants impacted specific cell signalling pathways, we examined the activities of not 
only BMP and Hedgehog cell signalling but also markers for a number of tyrosine 
kinase receptor mediated cell signalling pathways during different stages of both 
triple positive and triple negative tumour growth.  Compared with the normal, 
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immunohistochemical analysis demonstrated increased activation of BMP signalling 
investigated by the expression of p-Smad 1/5/8 staining as well as increased RTK 
staining for p-EGFR, p-FGFR1 and p-cMet (Figure 3). Semi-quantitative analysis of 
immunohistochemical staining using volocity software highlighted the onset of such 
signalling in all triple positive samples with particularly increased levels during stages 
II and III (Figure 4).  While the level of p-Smad 1/5/8 and p-cMet in triple positive 
samples was low during stage I, the levels of p-EGFR and p-FGFR1 were high even 
during stage I. Unlike triple positive tumours, the levels of p-FGFR1 and particularly 
p-EGFR in contrast were low in triple negative tumours (Figure 4). While the level of 
BMP signalling also increased in triple negative tumours, the level of p-cMet in triple 
negative samples showed only a moderate increase. The AKT and ERK1/2 
cascades are triggered by growth factors and cytokines acting through receptor 
tyrosine kinases.  Investigation of such down-stream targets of RTK signalling 
pathways further indicated the active involvement of RTK cell signalling as a large 
majority of the tumours showed high levels of pERK and pAKT activity (Figure 5). A 
small proportion of the tumours, however, also showed greatly reduced level of 
pAKT and pERK activity not only in triple negative (Figure 5) but also in some triple 
positive tumours (Figure 5).  Hedgehog signalling investigated by ptc1receptor 
expression did not show any specific changes in such tumours. 
 
Increased SULF1/SULF2 expression and RTK-mediated cell signalling 
following mammary tumour metastasis to lymph node: We also examined if 
SULF1/SULF2 expression or cell signalling activities changed in a set of primary 
triple positive mammary tumours that had metastasised to lymph nodes when 
compared with the original tumour in its primary location.  SULF1 as well as SULF2 
expression was maintained and quantitatively enhanced following metastasis to 
lymph node although the level of SULF2 decreased during late stage metastasis 
(Figure 6). The nature of SULF1/SULF2 splice variant following metastasis did not 
change as the metastasised cells still predominantly expressed the shorter variants. . 
The semi-quantitative analysis of immunohistochemical staining using volocity 
software also showed significant increases in HSPG sulfation, p-EGFR, pFGFR1, p-
cMet and BMP signalling analysed by p-Smad1/5/8 analysis during both earlier 
(stage II) and later (stage III) stages of metastasis (Figure 7). 
 
The differential cell signalling roles of Sulf1/Sulf2 variants in some mammary 
tumour derived cell lines: To examine the role of Sulf1 and Sulf2 variants in 
tumour growth, triple negative MDA-MB231 and estrogen receptor positive MCF7 
mammary tumour cell lines were individually transfected with full length and shorter 
Sulf1 and Sulf2 variants.  MDA-MB231 cells express only a trace amount of full 
length Sulf1 under normal culture conditions but not any Sulf2 (Figure 8) since the 
DNA sequencing of a shorter band (indicated by an asterisk) in Sulf2 lane showed it 
to be a non-specific zinc finger protein. The RT PCR analysis of MCF7 cell line in 
contrast did not only confirm it to express high level of Sulf2 as reported by others 
(Uchimura et al. 2006) but also detected the expression of a short Sulf1 variant that 
has not been previously reported (Figure 8.b). The DNA sequencing of this fragment 
confirmed it to lack exons 6, 7 & 8. The Sulf1/Sulf2 gene transfection of these cell 
lines inducing not only mRNA but also protein expression was apparent in all 





The over-expression of full length Sulf1 (HS1) in MDA-MB231 cells inhibited its in 
vitro growth while the over-expression of the shorter Sulf1 (HS1-678) variant 
promoted growth. The over-expression of full length (HS2) as well as its shorter 
variant (HS2-678) in MDA-MB231cells promoted its growth although the level of 
increase with HS2 was higher than with HS2-678 transfection (Figure 8.d). The 
addition of FGF2 to such transfected cells promoted growth in EGFP and HS1-678 
transfected cells and with only a marginal increase in HS2-678 transfected cells but 
reduced growth in HS2 transfected cells with a lower inhibition observed in HS1 
transfected cells (Figure 8.d). 
 
The over-expression of Sulf1 and Sulf2 variants in MCF7 cells promoted growth not 
only in HS1-678 and HS2-678 cells but also in HS2 transfected cells but with 
inhibition observed in HS1-transfected cells (Figure 8.e).  The addition of FGF2 to 
such transfected cells demonstrated increased growth in EGFP and HS1-678 
transfected cells but with no significant further growth but preservation in HS2-678 
transfected cells (Figure 8.e). 
 
The addition of cyclopamine to all MDA-MB231 transfected cells markedly inhibited 
in vitro growth while the addition of SHH ligand promoted growth in only the control 
EGFP transfected cells but inhibition in both full length and shorter Sulf1 and Sulf2 
transfected cells (Figure 8.f). The addition of cyclopamine to all MCF7 transfected 
cells also markedly inhibited in vitro growth while the addition of SHH ligand 
promoted growth not only in EGFP but also in HS1 and HS2 transfected cells but 





The present study demonstrated SULF1 expression not only in triple positive but 
also in triple negative mammary tumours during all stages of tumour growth although 
the SULF1 level was much lower in benign tumours. This contrasts with little or no 
SULF1 expression in normal mammary tissue. The major SULF1 variant expressed 
in these tumours was the shorter variant lacking catalytically active exon 6 although 
low levels of full length enzyme were also detected in some tumours. Up-regulation 
of SULF2 was also observed in both triple positive and triple negative mammary 
tumours, with the level of SULF2 expression being higher in triple negative than triple 
positive.  Although SULF2 was barely detectable in normal mammary tissue, 
significant levels of SULF2 were also observed in benign and hyperplastic mammary 
tissues.  As was the case with SULF1, it was the shorter SULF2 splice variant 
lacking catalytically active exon 6 that predominated in such tumours although low 
but significant levels of full length SULF2 were also apparent in some samples. 
Alternative splicing of exons can alter protein function and thus increase the 
functional diversity of proteins. Such splicing could contribute to functional versatility 
of proteins to increase the diversity of interaction networks. Shorter variants could 
affect tumour growth by titrating out the activity of the full length inhibitory variant by 
competing for ligand or receptor binding. High levels of both SULF1/SULF2 in not 
only triple positive but also in triple negative mammary tumours, highlights the 
SULF1/SULF2 independence from estrogen signalling. This differs from estrogen 
receptor mediated EGFR-signalling that was barely detectable in triple negative 
tumours unlike its high activity in estrogen-positive tumours. This thus indicates 
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variation in the mechanism of SULF1 and SULF2 function in triple positive versus 
triple negative tumours. Short SULF1/SULF2 variants in triple positive tumours are 
ideally suited to promote 6-O sulfate requiring receptor tyrosine kinase signalling but 
it is not clear which signalling pathways are promoted by shorter variants in triple 
negative tumours. The level of BMP and Hedgehog signalling was higher in triple 
negative than triple positive tumours that may also be facilitated by short variants or 
the balance of full length and shorter variants in these tumours. Enhanced Wnt 
signalling and Notch signalling has also been reported to play a role in triple negative 
tumours (Jamdade VS et al. 2015; Koval A et al. 2016; King TD et al. 2012) although 
Wnt signalling is believed to be promoted by full length Sulf1 and Sulf2 genes.  
  
The high levels of short SULF1/SULF2 variants observed during tumour growth also 
coincided with high levels of sulfation detected in triple positive as well as triple 
negative mammary tumours although 10E4 antibody has been reported to detect N-
sulfation (David G et al. 1992) and not 6-O sulfation modulated by SULF1/SULF2. 
The low level sulfation in normal mammary tissue, however, is clearly not related to 
the presence of full length SULF1 or SULF2 but the differential activity of the 
intracellular sulfotransferases. It is thus not surprising to observe increased RTK-
mediated cell signalling in mammary tumours, the activities of which would be 
enhanced by increased HS sulfation. For example, the level of EGFR and FGFR1 
RTK activity was greatly increased in triple positive but not in triple negative samples 
except for some increase during stage II. The level of cMet RTK was similarly greatly 
increased in triple positive mammary tumours, particularly during stages II and III 
while the increase was lower but still significant in triple negative tumours. The 
presence of significant levels of short SULF1 and SULF2 variants would support 
such RTK-mediated cell signalling in mammary tumours. We nevertheless 
acknowledge that increased sulfation in mammary tumours observed by antibody 
10E4 relates to N-sulfation and not 6,0 sulfation required for many RTK mediated 
cell signalling pathways.  N-sulfation, however, has been reported to be important for 
certain cell signalling pathways.  For example, defective N-sulfation of heparan 
sulfate proteoglycans has been shown to limit PDGF-BB binding and pericyte 
recruitment in vascular development (Abramsson A1 et al. 2007) although 
SULF1and SULF2 have also been shown to inhibit  PDGF signalling by 6-O 
desulfation (Takashima Y1 et al. 2016). PDGF signalling is thus regulated by both N-
sulfation and 6-O sulfation. N-sulfation or some factor requiring N-sulfation has also 
been shown to be important in the developing mammary gland (Bush KT1 et al. 
2012). 
 
Of all the RTK signalling pathways investigated in this study, the EGFR RTK activity 
demonstrated the clearest difference in triple positive versus triple negative tumours.  
For example, while triple positive mammary tumours demonstrated greatly increased 
EGFR RTK activity, triple negative tumours despite increased sulfation did not show 
any EGFR activity.  Differences in EGFR cell signalling in triple positive versus triple 
negative samples could relate to lack of ER signalling in these tumours. EGFR 
signalling despite short Sulf1 and Sulf2 abundance regulating HSPG sulfation in 
triple negative tumours thus could not be promoted due to critical dependence of 
EGFR activity on ER signalling (Britton et al. 2006). Triple negative tumours 
nevertheless showed some pERK and pAKT downstream signalling due presumably 
to some activation of cMet RTK activity although even BMP signalling has been 
reported to increase activities of such enzymes in some cases (Ye L et al. 2009). For 
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example, the BMPs have been reported to affect RTK activity indirectly by promoting 
VEGF activity to enhance angiogenesis in many cancer tissues (Dai J et al. 2004; 
Deckers MM et al. 2002).  A family of ligands that binds ErbB receptors 
(ErbB1/EGFR, ErbB2/Her-2/Neu, ErbB3 and ErbB4) plays an important role in breast 
cancer in which such receptors are over-expressed to promote tumour growth. When 
activated by ligand binding, this family of ErbB/EGFR receptor tyrosine kinases 
induces receptor dimerization, kinase activity and auto-phosphorylation to trigger 
downstream ERK1/2 and PI3K/AKT activation.  Phosphorylation of such downstream 
signalling molecules enhances tumour cell survival and proliferation. The EGFR 
activity In human mammary cancers is thus implicated in regulating cell growth and 
survival through its differential activity via ER response. The constitutive activation of 
the kinase pathways, however, may bypass inhibition of EGFR/HER2 tyrosine 
kinases, and develop insensitivity to drugs targeting these receptors. This is 
compatible with reported observations (Britton et al. 2006) that estrogen receptor 
modulates EGFR/kinase signalling in some tamoxifen-resistant breast cancer cells. 
 
To determine if SULF variant expression also correlated with some other cell 
signalling pathways, the immunocytochemical analysis also detected BMP signalling 
as revealed by downstream p-Smad 1,5,8 activation in both triple positive and triple 
negative tumours although some previous studies have shown BMP signalling 
restricted to only triple positive samples (Helms MW et al. 2005). The precise 
function of BMP signalling in breast cancer, however, is still unclear since specific 
BMP ligands have been shown to promote as well as inhibit cancer cell growth and 
migration including metastasis (Alarmo EL 2010) although most such studies are 
restricted to mainly cell line analyses. 
 
Breast cancer metastasis to lymph nodes showed further increase in not only BMP 
signalling but also RTK-mediated cell signalling including increased p-EGFR, p-
FGFR1 and p-cMet activities. Increased RTK signalling following metastasis is also 
compatible with further increased expression of short SULF1 variant during both 
earlier and later stages and SULF2 variant increase only during earlier stage. RTK 
signalling is implicated in tumour invasion and metastasis but how such different 
signalling pathways are specifically used for tumour invasion is not clear. It is 
possible that increased RTK activation facilitated by increased sulfation de-stabilises 
E-cadherin adhesions to induce epithelial mesenchymal transformation (EMT) 
required for tumour cell metastasis to the lymph node or any other tissue (Qian X et 
al. 2004).  
 
The involvement of Sulf1/Sulf2 splice variants in mammary tumour progression was 
further supported by our in vitro investigation of their over-expression in MCF7 and 
MDA-MB231 mammary tumour cell lines.  The MCF7 cell line, however, unlike MDA-
MB231 already expresses not only full length Sulf2 (Uchimura et al. 2006) but also a 
shorter variant of Sulf1 that we observed in the present study. Nevertheless, full 
length Sulf1 unlike the shorter Sulf1 variant inhibited MCF7 in vitro growth whereas 
over-expression of both full length and shorter Sulf2 promoted growth but with less 
clearer effects on FGF2 activity. It is also remarkable that the growth of MCF7 cell 
line was inhibited by full length Sulf1 considering that it already expresses high level 
of full length Sulf2 thus highlighting some inherent differences in Sulf1 and Sulf2 
activities despite their high level of homology and similarity of function. It is possible 
that the expression of full length Sulf2 in MCF7 is sufficiently counteracted by the 
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presence of short Sulf1 variant so that full length Sulf1 can exert its inhibitory activity.  
Sulf1 over-expression in MDA-MB231 cell line that normally does not express any 
Sulfs with the exception of a trace amount of full length Sulf1 demonstrated clear 
differences in their effects on cellular growth as full length Sulf1 inhibited while short 
Sulf1 variant promoted in vitro growth. Unlike the full length Sulf1, over-expression of 
full length Sulf2 did not inhibit MDA-MB231 in vitro growth but instead promoted 
growth as did the shorter variant of Sulf2. The differential inhibitory effect of full 
length Sulf1 in comparison with growth enhancing effect of shorter Sulf1 was also 
apparent from their differential inhibitory and stimulatory effects on FGF signalling.  
While both short and full length Sulf2 promoted MDA-MB231 growth, the FGF2 
activity was inhibited by full length but not the shorter Sulf2 variant. The mechanism 
of such full length Sulf1 and Sulf2 differences is not clear considering that both these 
enzymes have similar 6-O de-sulfation function and nor can it be explained by their 
differential cell surface signalling and ECM sequestering activities observed in vivo 
tissues. The SULF1 and SULF2 functional similarities observed in normal tissues 
thus not always hold true in tumour tissues due presumably to multiple mutations.  
Understanding the interactions between different components of cell signalling 
pathways could provide new avenues in devising novel therapeutic strategies for 
drug resistant mammary tumours. This study shows that both SULF1 and SULF2 are 
overexpressed in breast cancer in which they could promote tumour growth and 
metastasis. Targeting SULF1/SULF 2 may offer alternative strategies to develop 
novel cancer therapies.  In conclusion, short SULF variants predominate in 
mammary tumours to stimulate growth and metastasis by protecting HS sulfation 




Materials and Methods  
 
Tissue samples and immunocytochemical staining procedure: Human 
mammary tumour tissue arrays containing both normal and cancer tissue samples 
were obtained from US Biomax and included two or three cores from each patient 
sample. This analysis also included some other samples provided by Addenbroke 
hospital Cambridge as part of another study (Gill et al. 2011). The number of 
samples for each group were: normal: 11, hyperplasia: 6, benign: 6, triple positive 
invasive ductal carcinoma stage I: 35, stage II: 172, stage III: 75; triple negative 
invasive ductal carcinoma stage I: 6, stage II: 22, stage III: 12; number of triple 
positive invasive ductal carcinomas in primary location: 50 and following metastasis 
to lymph node: 50. The pattern of SULF1/SULF2 expression in such samples was 
examined using antibodies to these enzymes, the specificities of which have 
previously been described (Gill et al. 2011; Gill et al. 2012; Gill et al. 2010; Sahota 
and Dhoot 2009). Single or double immunofluorescence was used to stain paraffin 
sections of human tissues with different SULF1, SULF2 and some commercial 
antibodies (Gill et al. 2010; Gill et al. 2014) listed in table 1. The binding of mouse 
primary antibodies was detected using Alexa Fluor 488 fluorochrome-conjugated 
goat anti-mouse IgG diluted 1/400. Binding to total SULF1 (full length and all splice 
variants) by SULF1 antibody C (1/200) was visualised using goat anti-rabbit 
biotinylated IgG followed by streptavidin-conjugated Alexa Fluor 594. Sequential 
double immunofluorescence using two different rabbit antibodies included labelling 
exon specific antibodies with Alexa Fluor 488 followed by total SULF1 or SULF2 
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antibodies labelled with Alexa Fluor 594 (Figure 1.c). The double 
immunofluorescence procedure using two different rabbit antibodies sequentially 
always included staining with an exon specific antibody detected by Alexa Fluor 488 
label first. The 2nd part of double immunofluorescence always included staining with 
an antibody to total SULF1 (antibody C) or total SULF2 (antibody D). To ensure no 
cross reaction with the two rabbit antibodies, the staining patterns were also 
ascertained with individual primary antibodies before their application in the double 
immunofluorescence procedure. Sections treated with pre-immune rabbit sera were 
similarly incubated with fluorochrome-labelled secondary antibodies as controls (not 
shown).  All fluorochrome-labelled secondary antibodies were diluted 1/400. All 
appropriately diluted (table 1) primary antibody reactions were incubated overnight at 
4 °C followed by secondary antibody incubations for 1 hour each at room 
temperature. Labelled tissue sections were mounted in fluorescent mounting 
medium (Sigma Aldrich) containing 2.5 μg/ml DAPI for nuclear visualisation and 
photographed using a Leica DM4000B fluorescent microscope. Quantification of the 
individual fluorescent images was carried out using Volocity software by measuring 
average pixel count/image. 
Cell culture and transfection: Based on our splice variant analysis of canine and 
human Sulf1 and Sulf2 genes described previously (Gill et al. 2011; Gill et al. 2012; 
Gill et al. 2014), human Sulf1 and Sulf2 cDNA constructs cloned in pcDNA3 were 
transfected for over-expression in MCF7 and MDA-MB231 cell lines obtained from 
ATCC. Such cell lines purchased from ATCC were grown in RPMI (MCF7) or 
Dulbecco׳s modified Eagle׳s (DMEM) medium (MDA.MB231) with 10%FCS.  
Sulf1/Sulf2 variants were transfected with an EGFP expression vector while the 
control cells were transfected with EGFP/pcDNA3 alone using the Biorad 
TransFectin reagent. To enrich the mixed population of transfected cells, the normal 
growth medium was changed to DMEM/10%FCS with 800 µg/ml G418 following 
48 hours of growth in the normal medium. The Sulf1/Sulf2 over-expression by 
transfection was confirmed by the RT PCR analysis. Such transfected cells were 
used for in vitro and in vivo assays following 2–6 weeks of growth in G418 containing 
medium. For in vitro proliferation assays, 10,000 cells/well were seeded in multiple 
24-well plates and the trypsinised cells were counted after 5 days of culture. In 
addition to each sample consisting of a minimum of three replicates for each stage, 
each experiment was repeated three times. 
 
RT PCR: To examine the expression of Sulf1 and Sulf2 splice variants in cell lines, 
total RNA was prepared from mammary tumour cell lines MCF7 and MDA-MB231 
using Trizol. RNA was also prepared from these cell lines following their transfection 
with only EGFP (as control) and with full length or short Sulf1 or Sulf2 variant as 
described before (Gill et al. 2014). Equivalent amount of total RNA (1 μg) for each 
sample was reverse-transcribed into cDNA using SuperScript II reverse transcriptase 
(Invitrogen), using random primers (Invitrogen, Paisley, UK) for RT-PCR analysis.  
The PCR of cDNA was carried out using primers to exons 5 and 9 of the catalytic 
domain that we have shown to splice out exons 6–8 in different combinations in our 
earlier study (Gill et al. 2014; Zaman et al. 2016). The primers: 5’-
CGAGGTTCAGAGGACGGATA-3’ and 5’-GCCTCTCCACAGAATCATCC-3’ were 
used to amplify 804-bp fragment of catalytic domain, nucleotides 83–886 bp of Sulf1. 
Primers, 5’-CAACTGTGTTCTCCCTGCTGGGT-3’ & 5’-
CTGGAGCATGTTGGTGAATTCC-3′ were used to amplify a region of Sulf2 catalytic 
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domain, nucleotides 38-843 (Zaman et al. 2016). PCR fragments following 40 
amplification cycles separated in 2% agarose gels were cut out and purified to verify 
their identity by DNA sequencing (GATC Biotech). Primers 5′-
CTATGAGCTGCCTGACGGTC-3′ and 5′-AGTTTCATGGATGCCACAGG-3′ were 
used to amplify 114bp β-actin (nucleotides 798–912 bp) to normalise the sample 
loading. 
 
Statistical analysis: Statistical analysis was preformed using either a one-way 
ANOVA or a two-way ANOVA, where data depicting a P-value < 0.05 was 
considered statistically significant. To enable multiple comparisons a Tukey’s test 
was used to determine significant variation between Sulf transfects to their eGFP 
controls or between full length Sulf isoforms and their shorter variants.  
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Figure 1: (a).: Pattern of SULF1 expression in tissue sections of normal, 
hyperplastic, benign and triple positive and triple negative ductal carcinomas during 
stages I, II and III examined by double immunofluorescence procedure.  SULF1 is 
detected using antibody A against exon 6 (AlexaFluor488) and antibody C against 
total SULF1 (AlexaFluor594). The superimposed pictures show exon 6-containing 
SULF1 as yellow and exon-6 lacking SULF1 (total) as red.  (b) shows semi-
quantitative analysis of SULF1(yellow=full length; red=total) expression during 
different stages of triple positive and triple negative invasive ductal carcinoma growth 
in comparison with normal, hyperplastic and benign tumours. Quantification of the 
individual fluorescent images was carried out using Volocity software by measuring 
average pixel count, **p<0.001, *p<0.01. The number of samples for this analysis 
were: normal: 11, hyperplasia: 6, benign: 6, triple positive invasive ductal carcinoma 
stage I: 35, stage II: 172, stage III: 75; triple negative invasive ductal carcinoma 
stage I: 6, stage II: 22, stage III: 12. (c) highlights the location of Sulf1 and Sulf2 
peptides used for antibody production (not to scale). 
 
Figure 2: (a): Pattern of SULF2 expression in tissue sections of normal, hyperplastic, 
benign and triple positive and triple negative ductal carcinomas during stages I, II 
and III examined by double immunofluorescence procedure.  SULF2 is detected 
using antibody N against exon 6 (AlexaFluor488) and antibody D against total 
SULF2 (AlexaFluor594). The superimposed pictures show exon 6-containing SULF2 
as yellow and exon-6 lacking SULF2 (total) as red. (b) shows semi-quantitative 
analysis of SULF2 (yellow=full length; red=total) expression during different stages of 
triple positive and triple negative invasive ductal carcinoma growth in comparison 
with normal, hyperplastic and benign tumours. Quantification of the individual 
fluorescent images was carried out using Volocity software by measuring average 
pixel count, **p<0.001, *p<0.01. The number of samples for this analysis were: 
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normal: 11, hyperplasia: 6, benign: 6, triple positive invasive ductal carcinoma stage 
I: 35, stage II: 172, stage III: 75; triple negative invasive ductal carcinoma stage I: 6, 
stage II: 22, stage III: 12. 
 
Figure 3: Level of N-sulfation (using antibody 10E4) and growth factor signalling  
activities (using antibodies to phosphorylated EGFR, FGFR1, cMet and Smad,1,5,8) 
in normal mammary tissue and during different stages (I, II, III) of triple positive 
invasive ductal mammary tumours examined by immunofluorescence 
(AlexaFluor488) superimposed with blue DAPI nuclear stain. 
 
Figure 4:  Semi-quantitative analysis of HS N-sulfation (a) and activities of different 
cell signalling pathways (b-f: as indicated on the side of each set of histograms) in 
normal, hyperplastic and benign tumour tissues and during different stages of growth 
of both triple positive and triple negative invasive ductal carcinomas. The individual 
fluorescent images were used for pixel count to quantify relative levels of expression 
using Volocity software, **p<0.001, *p<0.01. The number of samples for this analysis 
were: normal: 11, hyperplasia: 6, benign: 6, triple positive invasive ductal carcinoma 
stage I: 35, stage II: 172, stage III: 75; triple negative invasive ductal carcinoma 
stage I: 6, stage II: 22, stage III: 12. 
 
Figure 5: Patterns of pERK and pAKT signalling activities revealed by red 
immunohistochemical stain (superimposed with blue nuclear DAPI stain) in normal 
and three different stage III triple positive and triple negative patient samples of 
invasive ductal carcinoma. The staining patterns demonstrate regional variation as 
well as variation in the level of their activities in individual patient biopsies. 
 
Figure 6: (a) & (b): Patterns of SULF1 and SULF2 expression in triple positive 
invasive ductal carcinomas in their primary location in mammary tumour and the 
same tumour following metastasis to lymph node. SULF1 is detected using antibody 
A against exon 6 (AlexaFluor488) and antibody C against total SULF1 
(AlexaFluor594). The superimposed pictures show exon 6-containing SULF1 as 
yellow and total SULF1 as red. SULF2 is detected using antibody N against exon 6 
(AlexaFluor488) and antibody D against total SULF2 (AlexaFluor594). The 
superimposed pictures show exon 6-containing SULF2 as yellow and total SULF2 as 
red.  Also shown in this figure is semi-quantitative analysis of changes in SULF1 (a1) 
and SULF2 (b1), (yellow=full length; red=total). 
 
Figure 7: (a): Pattern of pEGFR1 expression in triple positive invasive ductal 
carcinoma in its primary location in mammary tumour and the same tumour following 
metastasis to lymph node, with p-EGFR staining appearing green with blue DAPI 
nuclear counterstain.  (b-g) show semi-quantitative analysis of changes in N-sulfation 
(b) and different growth factor signalling activities (pEGFR, pFGFR1, p-cMet, ptc1, 
Smad1,5,8) as indicated in triple positive invasive ductal carcinoma stages II and III 
in primary mammary tumour location and following metastasis to lymph node,  
**p<0.001, *p<0.01. The number of samples for this analysis were: triple positive 
invasive ductal carcinomas in primary location: 50 and following metastasis to lymph 
node: 50.   
Figure 8: (a) & (b): Pattern of Sulf1/Sulf2 expression and the over-expression of full 
length Sulf1 (HS1), full length Sulf2 (HS2) and shorter Sulf1 (HS1-678) and shorter 
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Sulf2 (HS2-678) by transfection in MDA-MB231 (a) and MCF7 (b) cell lines 
examined by RT PCR analysis as are also the cells transfected with only EGFP.  (c): 
In addition to RT PCR, transfected cells were also examined by EGFP expression 
and Sulf2 expression by immunofluorescence, i=MDA-MB231 cells transfected with 
HS2 showing eGFP expression, ii= MDA-MB231 showing Sulf2 protein expression 
by immunofluorescence, iii= untransfected MDA-MB231 cells showing lack of Sulf2 
protein expression by immunofluorescence.  The effect of individual Sulf1 and Sulf2 
variant over-expression was examined on growth of such cells over 5 days in both 
the presence and absence of 50ng/ml FGF2 in MDA-MB231 cells (d) and MCF7 (e) 
cells. Also examined was the effect of Sulf1 and Sulf2 variant over-expression on 
Hedgehog signalling stimulation using SHH (10ng/ml) and inhibition by Cyclopamine 
(10µM) on the growth of MDA-MB231 (f) and MCF7 (g) cells following 5 days in vitro 
growth, error bars: means+SD of samples, **p<0.001, *p<0.01. Each proliferation 
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